AbstractThe human immunodeficiency virus type-1 (HIV-1) vaccine candidate F4/AS01 has previously been shown to induce potent and persistent polyfunctional CD4+ T-cell responses in HIV-1-seronegative volunteers. This placebo-controlled study evaluated two doses of F4/AS01 1-month apart in antiretroviral treatment (ART)-experienced and ART-naïve HIV-1-infected subjects (1:1 randomisation in each cohort). Safety, HIV-1-specific CD4+ and CD8+ T-cell responses, absolute CD4+ T-cell counts and HIV-1 viral load were monitored for 12 months post-vaccination. Reactogenicity was clinically acceptable and no vaccine-related serious adverse events were reported. The frequency of HIV-1-specific CD4+ T-cells 2 weeks post-dose 2 was significantly higher i...
Sequential prime-boost or co-administration of HIV vaccine candidates based on an adjuvanted clade B...
Novel tuberculosis vaccines should be safe, immunogenic, and effective in various population groups,...
BACKGROUND: Novel tuberculosis vaccines should be safe, immunogenic, and effective in various popula...
AbstractThe human immunodeficiency virus type-1 (HIV-1) vaccine candidate F4/AS01 has previously bee...
Background. This phase I/II partially blinded, randomized, dose-ranging study assessed the safety an...
The impact of the investigational human immunodeficiency virus type 1 (HIV-1) F4/AS01(B) vaccine on ...
AbstractA recombinant fusion protein (F4) consisting of HIV-1 p17, p24, reverse transcriptase (RT) a...
Introduction : Vaccines may be key components of a curative strategy for HIV-1. We investigated whet...
With the advancement in anti-retroviral therapy (ART) regimens there has been a significant improvem...
BACKGROUND: We conducted a Phase I dose escalation trial of ADVAX, a DNA-based candidate HIV-1 vacci...
Trial Design Previous studies suggested that poxvirus-based vaccines might be instrumental in the t...
With the advancement in anti-retroviral therapy (ART) regimens there has been a significant improvem...
Sequential prime-boost or co-administration of HIV vaccine candidates based on an adjuvanted clade B...
IntroductionFunctional cure has been proposed as an alternative to lifelong antiretroviral therapy a...
Background: VRC01 is an HIV-1 CD4 binding site broadly neutralizing antibody (bnAb) that is active a...
Sequential prime-boost or co-administration of HIV vaccine candidates based on an adjuvanted clade B...
Novel tuberculosis vaccines should be safe, immunogenic, and effective in various population groups,...
BACKGROUND: Novel tuberculosis vaccines should be safe, immunogenic, and effective in various popula...
AbstractThe human immunodeficiency virus type-1 (HIV-1) vaccine candidate F4/AS01 has previously bee...
Background. This phase I/II partially blinded, randomized, dose-ranging study assessed the safety an...
The impact of the investigational human immunodeficiency virus type 1 (HIV-1) F4/AS01(B) vaccine on ...
AbstractA recombinant fusion protein (F4) consisting of HIV-1 p17, p24, reverse transcriptase (RT) a...
Introduction : Vaccines may be key components of a curative strategy for HIV-1. We investigated whet...
With the advancement in anti-retroviral therapy (ART) regimens there has been a significant improvem...
BACKGROUND: We conducted a Phase I dose escalation trial of ADVAX, a DNA-based candidate HIV-1 vacci...
Trial Design Previous studies suggested that poxvirus-based vaccines might be instrumental in the t...
With the advancement in anti-retroviral therapy (ART) regimens there has been a significant improvem...
Sequential prime-boost or co-administration of HIV vaccine candidates based on an adjuvanted clade B...
IntroductionFunctional cure has been proposed as an alternative to lifelong antiretroviral therapy a...
Background: VRC01 is an HIV-1 CD4 binding site broadly neutralizing antibody (bnAb) that is active a...
Sequential prime-boost or co-administration of HIV vaccine candidates based on an adjuvanted clade B...
Novel tuberculosis vaccines should be safe, immunogenic, and effective in various population groups,...
BACKGROUND: Novel tuberculosis vaccines should be safe, immunogenic, and effective in various popula...